Satellite Symposium at EADO 2022
Friday, 22 April
Drinks and Light Snacks
14:00 – 14:30
Panel Discussions with Patient Video
14:30 – 15:30
Barceló Sevilla Renacimiento Hotel & Convention Centre
Room 4, Ground Floor
Avenida Alvaro Alonso Barba 41092
Sevilla, Spain
During the 18th EADO Congress, please join our multidisciplinary expert faculty for this interactive panel discussion offering privileged insights into the evolving nonmelanoma skin cancer (NMSC) treatment paradigm.
Core topics include the identification of difficult-to-treat disease and evidence-based strategies for immunotherapy selection in cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). To augment these insights, a patient panelist will highlight aspects of their own NMSC treatment journey via video commentary.
FACULTY
Prof. Axel Hauschild, MD (Chair)
Professor, Dermatology
Head of Dermato-oncology
Department of Dermatology
University of Kiel
Kiel, Germany
David M. Miller, MD, PhD, FAAD
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Mass General Cancer Center
Boston, United States
Vishal Anil Patel, MD, FAAD, FACMS
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology,
George Washington University School of Medicine & Health Sciences
Washington DC, United States
PROGRAM AGENDA
Prof. Axel Hauschild, MD
All Faculty plus Patient Video Commentary
All Faculty plus Patient Video Commentary
All Faculty plus Patient Video Commentary
All Faculty
WHO SHOULD ATTEND?
This activity is intended for medical oncology and dermatology clinicians who manage patients with nonmelanoma skin cancer.
LEARNING OBJECTIVES FOR ATTENDEES
Upon completion of this activity, participants should be better able to:
- Identify patients with difficult-to-treat nonmelanoma skin cancer (NMSC) based on current staging systems, risk factors, and guidelines
- Select appropriate immunotherapy for advanced NMSC based on available data and approved indications
Provider Statement
This educational activity was independently developed by RMEI Medical Education, LLC. All faculty and planner relevant financial relationships were identified and mitigated and RMEI Medical Education, LLC has reviewed the content and determined it to be fair, balanced, and without commercial bias.
Supporter Statement
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.
FEE INFORMATION
There is no fee for this educational activity.
FOLLOW RMEI
Additional educational activities offered by RMEI Medical Education, LLC can be found
at www.RMEI.com or by calling toll-free (866) 770-RMEI.